INNOVIVA, INC. Income Taxes Paid
INNOVIVA, INC. (INVA) reported Income Taxes Paid of $12.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-05
- INNOVIVA, INC. income taxes paid, net for the quarter ending 2026-06-30 was $11.69M, a 2.09% decline year-over-year.
- INNOVIVA, INC. income taxes paid, net for the quarter ending 2026-03-31 was $670.00K.
- INNOVIVA, INC. income taxes paid, net for the quarter ending 2025-12-31 was $6.04M.
- INNOVIVA, INC. income taxes paid, net for the quarter ending 2025-09-30 was $1.13M, a 90.44% decline year-over-year.
- INNOVIVA, INC. income taxes paid, net for fiscal 2025 was $19.11M, a 62.07% increase from fiscal 2024.
- INNOVIVA, INC. income taxes paid, net for fiscal 2024 was $11.79M.
- INNOVIVA, INC. income taxes paid, net for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- INNOVIVA, INC. income taxes paid, net for fiscal 2022 was $53.85M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $12.36M 10-Q · filed 2026-08-05 | $18.41M derived: sum of 3 quarters · filed 2026-08-05 | $19.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $670.00K 10-Q · filed 2026-05-06 | $6.71M derived: sum of 2 quarters · filed 2026-05-06 | $7.84M derived: sum of 3 quarters · filed 2026-05-06 | $19.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.17M derived: sum of 2 quarters · filed 2026-02-25 | $19.11M derived: sum of 3 quarters · filed 2026-08-05 | $19.11M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.07M derived: sum of 2 quarters · filed 2026-08-05 | $13.07M 10-Q · filed 2025-11-05 | $13.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $11.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.94M 10-Q · filed 2026-08-05 | $11.94M derived: sum of 3 quarters · filed 2026-08-05 | $23.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $11.79M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.79M derived: sum of 2 quarters · filed 2026-02-25 | $11.79M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $11.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $11.79M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $53.85M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $3.86M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 10-K/A · filed 2024-03-05 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |